Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML).

DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Primary tabs

Ravoet, C Mineur, P. Robin, V. Debusscher, L. Bosly, André [UCL] Martiat, P. et al.[show all]

Document type	Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection
Publication date	2002
Language	Anglais
Conference	"44th Annual Meeting of the American-Society-of-Hematology", PHILADELPHIA(Pennsylvania) (Dec 06-10, 2002)
Journal information	"Blood" - Vol. 100, no. 11, p. 794A (2002)
Peer reviewed	yes
issn	0006-4971
e-issn	1528-0020
Publisher	Amer Soc Hematology (Washington)
Affiliation	UCL - Autre
Links	http://hdl.handle.net/2078.1/61659[Handle]

Bibliographic reference	Ravoet, C ; Mineur, P. ; Robin, V. ; Debusscher, L. ; Bosly, André ; et. al. Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML)..44th Annual Meeting of the American-Society-of-Hematology (PHILADELPHIA(Pennsylvania), Dec 06-10, 2002). In: Blood, Vol. 100, no. 11, p. 794A (2002)
Permanent URL	http://hdl.handle.net/2078.1/61659